{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T06:11:55Z","timestamp":1782799915518,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone &amp; IGF Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ghir.2020.01.003","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T12:17:21Z","timestamp":1579609041000},"page":"38-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Development of a novel assay for IGFBP-2 complexed with IGF-I and-II in human serum"],"prefix":"10.1016","volume":"51","author":[{"given":"Jonas","family":"Agerholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8237-0889","authenticated-orcid":false,"given":"Rikke","family":"Hjortebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrick","family":"Espelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben Riis","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Folkersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Bjerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1481-3278","authenticated-orcid":false,"given":"Jan","family":"Frystyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2020.01.003_bb0005","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.exger.2014.08.002","article-title":"Protein molecular forms of insulin-like growth factor binding protein-2 change with aging","volume":"58","author":"\u0160underi\u0107","year":"2014","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.ghir.2020.01.003_bb0010","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1517\/14728222.2014.858698","article-title":"Insulin growth factor binding proteins as therapeutic targets in type 2 diabetes","volume":"18","author":"Hjortebjerg","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ghir.2020.01.003_bb0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.beem.2013.08.010","article-title":"Determination of IGFs and their binding proteins","volume":"27","author":"Hjortebjerg","year":"2013","journal-title":"Best Pract. Res."},{"key":"10.1016\/j.ghir.2020.01.003_bb0020","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ghir.2007.08.005","article-title":"Assessing the potential usefulness of IGF-related peptides and adiponectin for predicting disease risk","volume":"18","author":"Belobrajdic","year":"2008","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.ghir.2020.01.003_bb0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/eje.1.02218","article-title":"Changes in bioactive IGF-I and IGF-binding protein-1 during an oral glucose tolerance test in patients with liver cirrhosis","volume":"155","author":"Chen","year":"2006","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2020.01.003_bb0030","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1046\/j.1365-2265.2003.01791.x","article-title":"The circulating IGF-system and its relationship with 24-h glucose regulation and insulin sensitivity in healthy subjects","volume":"58","author":"Frystyk","year":"2003","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2020.01.003_bb0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tem.2009.01.002","article-title":"IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis","volume":"20","author":"Wheatcroft","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ghir.2020.01.003_bb0040","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.beem.2015.07.002","article-title":"Physiology and pathophysiology of IGFBP-1 and IGFBP-2 \u2013 Consensus and dissent on metabolic control and malignant potential","volume":"29","author":"Hoeflich","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2020.01.003_bb0045","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1210\/jc.2009-0875","article-title":"The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity","volume":"94","author":"Arafat","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2020.01.003_bb0050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3346\/jkms.1999.14.4.401","article-title":"Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients","volume":"14","author":"Lee","year":"1999","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.ghir.2020.01.003_bb0055","article-title":"Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor Survival","volume":"8","author":"Guo","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ghir.2020.01.003_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fendo.2015.00025","article-title":"IGF-binding protein 2 - oncogene or tumor suppressor?","volume":"6","author":"Pickard","year":"2015","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ghir.2020.01.003_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10585-014-9647-4","article-title":"Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer?","volume":"31","author":"Hu","year":"2014","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ghir.2020.01.003_bb0070","first-page":"17","article-title":"Investigation of IGF2, IGFBP2 and p63 proteins in rhabdomyosarcoma tumors","volume":"33","author":"Yu","year":"2017","journal-title":"GH IGF Res."},{"key":"10.1016\/j.ghir.2020.01.003_bb0075","first-page":"33","article-title":"The insulin-like growth factor family and breast cancer prognosis: a prospective cohort study among postmenopausal women in Denmark","volume":"44","author":"Kalledsoe","year":"2019","journal-title":"GH IGF Res."},{"key":"10.1016\/j.ghir.2020.01.003_bb0080","first-page":"801","article-title":"Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions","volume":"18","author":"Rajaram","year":"1997","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ghir.2020.01.003_bb0085","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/er.2001-0033","article-title":"Cellular actions of the insulin-like growth factor binding proteins","volume":"23","author":"Firth","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ghir.2020.01.003_bb0090","first-page":"3","article-title":"Insulin-like growth factors and their binding proteins: biological actions","volume":"16","author":"Jones","year":"1995","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ghir.2020.01.003_bb0095","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1210\/endo.140.12.7169","article-title":"Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain","volume":"140","author":"Hoeflich","year":"1999","journal-title":"Endocrinol."},{"key":"10.1016\/j.ghir.2020.01.003_bb0100","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1038\/sj.onc.1210397","article-title":"IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells","volume":"26","author":"Perks","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ghir.2020.01.003_bb0105","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1210\/endo-122-5-2071","article-title":"The ontogeny and regulation of a 31,000 molecular weight insulin-like growth factor-binding protein in fetal porcine plasma and sera","volume":"122","author":"McCusker","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2020.01.003_bb0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jcem-53-1-100","article-title":"Plasma somatomedin-binding proteins in hypopituitarism: changes during growth hormone therapy","volume":"53","author":"Hintz","year":"1981","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2020.01.003_bb0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-13-0661","article-title":"Serum levels of bioactive IGF1 and physiological markers of aging in healthy adults","volume":"170","author":"Vestergaard","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2020.01.003_bb0120","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1210\/jc.2017-00033","article-title":"Insulin-like growth factor bioactivity, stanniocalcin-2, pregnancy-associated plasma protein-a, and IGF-binding protein-4 in pleural fluid and serum from patients with pulmonary disease","volume":"102","author":"Espelund","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2020.01.003_bb0125","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1210\/jc.2013-3060","article-title":"Age- and sex-specific reference intervals across life span for insulin-like growth factor binding protein 3 (IGFBP-3) and the IGF-I to IGFBP-3 ratio measured by new automated chemiluminescence assays","volume":"99","author":"Friedrich","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2020.01.003_bb0130","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1210\/jc.2013-3059","article-title":"Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations","volume":"99","author":"Bidlingmaier","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2020.01.003_bb0135","first-page":"169","article-title":"Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II","volume":"5","author":"Frystyk","year":"1995","journal-title":"Growth Reg."},{"key":"10.1016\/j.ghir.2020.01.003_bb0140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/EJE-13-0835","article-title":"Effects of raloxifene and estrogen on bioactive IGF1 in GH-deficient women","volume":"170","author":"Birzniece","year":"2014","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2020.01.003_bb0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2369-14-80","article-title":"Effect of hyperinsulinemia during hemodialysis on the insulin-like growth factor system and inflammatory biomarkers: a randomized open-label crossover study","volume":"14","author":"Reinhard","year":"2013","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ghir.2020.01.003_bb0150","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1210\/jc.2002-021349","article-title":"Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, \u22122, and -3 serum levels in patients with active thyroid eye disease","volume":"88","author":"Krassas","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4\u20135","key":"10.1016\/j.ghir.2020.01.003_bb0155","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clinbiochem.2014.11.022","article-title":"PAPP-A and IGFBP-4 fragment levels in patients with ST-elevation myocardial infarction treated with heparin and PCI","volume":"48","author":"Hjortebjerg","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ghir.2020.01.003_bb0160","first-page":"7","article-title":"IGFBP-4 and PAPP-A in normal physiology and disease","volume":"41","author":"Hjortebjerg","year":"2018","journal-title":"GH IGF Res."},{"key":"10.1016\/j.ghir.2020.01.003_bb0165","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12079-015-0261-2","article-title":"IGFBP-2 - taking the lead in growth, metabolism and cancer","volume":"9","author":"Yau","year":"2015","journal-title":"J. Cell Comm. Signal."},{"key":"10.1016\/j.ghir.2020.01.003_bb0170","first-page":"234","article-title":"Interstitial fluid contains higher in vitro IGF bioactivity than serum: A study utilizing the suction blister technique","volume":"22","author":"Espelund","year":"2012","journal-title":"GH IGF Res."},{"key":"10.1016\/j.ghir.2020.01.003_bb0175","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1210\/jc.2017-00696","article-title":"Effects of prednisolone on serum and tissue fluid IGF-I receptor activation and post-receptor signaling in humans","volume":"102","author":"Ramshanker","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"31","key":"10.1016\/j.ghir.2020.01.003_bb0180","doi-asserted-by":"crossref","first-page":"32266","DOI":"10.18632\/oncotarget.5010","article-title":"PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma","volume":"6","author":"Thomsen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ghir.2020.01.003_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2016.00002","article-title":"IGF-binding proteins in type-1 diabetes are more severely altered in the presence of complications","volume":"7","author":"Sharma","year":"2016","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ghir.2020.01.003_bb0190","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.012203","article-title":"Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays","volume":"10","author":"Zhi","year":"2011","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.ghir.2020.01.003_bb0195","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1464-5491.2003.00921.x","article-title":"The relationship between the circulating IGF system and the presence of retinopathy in Type 1 diabetic patients","volume":"20","author":"Frystyk","year":"2003","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ghir.2020.01.003_bb0200","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12020-019-01915-y","article-title":"Serum IGF-binding protein 2 (IGFBP-2) concentrations change early after gastric bypass bariatric surgery revealing a possible marker of leptin sensitivity in obese subjects","volume":"65","author":"Ceccarini","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.ghir.2020.01.003_bb0205","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-2006-924320","article-title":"Insulin-like growth factor binding protein-2 (igfbp-2) is a marker for the metabolic syndrome","volume":"7","author":"Heald","year":"2006","journal-title":"Exp. Clin. Endocrinol. Diab."},{"key":"10.1016\/j.ghir.2020.01.003_bb0210","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/(SICI)1520-7560(199909\/10)15:5<314::AID-DMRR56>3.0.CO;2-E","article-title":"Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes","volume":"15","author":"Frystyk","year":"1999","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.ghir.2020.01.003_bb0215","first-page":"100","article-title":"Clinical studies of IGFBP-2 by radioimmunoassay","volume":"3","author":"Blum","year":"1993","journal-title":"Growth Regul."},{"key":"10.1016\/j.ghir.2020.01.003_bb0220","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1078-0432.CCR-0672-2","article-title":"Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer","volume":"10","author":"Baron-Hay","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ghir.2020.01.003_bb0225","first-page":"1031","article-title":"Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients","volume":"76","author":"Cohen","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2020.01.003_bb0230","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1054\/bjoc.2000.1462","article-title":"Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer","volume":"83","author":"Renehan","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ghir.2020.01.003_bb0235","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1515\/CCLM.2008.349","article-title":"Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population","volume":"46","author":"Krebs","year":"2008","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["Growth Hormone &amp; IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637420300034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637420300034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:51:45Z","timestamp":1761087105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637420300034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":47,"alternative-id":["S1096637420300034"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2020.01.003","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel assay for IGFBP-2 complexed with IGF-I and-II in human serum","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2020.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}